Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- Key technology for a future without fossil fuelsIn June and July 2025, catalyst researcher Nico Fischer spent some time at HZB. It was his sabbatical, he was relieved of his duties as Director of the Catalysis Institute in Cape Town for several months and was able to focus on research only. His institute is collaborating with HZB on two projects that aim to develop environmentally friendly alternatives using innovative catalyst technologies. The questions were asked by Antonia Rötger, HZB.
- 5000th patient treated with protons for eye tumoursFor more than 20 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
- Iridium-free catalysts for acid water electrolysis investigatedHydrogen will play an important role, both as a fuel and as a raw material for industry. However, in order to produce relevant quantities of hydrogen, water electrolysis must become feasible on a multi-gigawatt scale. One bottleneck is the catalysts required, with iridium in particular being an extremely rare element. An international collaboration has therefore investigated iridium-free catalysts for acidic water electrolysis based on the element cobalt. Through investigations with various methods, among them experiments at the LiXEdrom at the BESSY II X-ray source in Berlin, they were able to elucidate processes that take place during water electrolysis in a cobalt-iron-lead oxide material as the anode. The study is published in Nature Energy.